

Whistleblower Lawsuit! Government Medicare Data Shows 48,465 Dead Following COVID Shots -Remdesivir Drug Has 25% Death Rate!

By Brian Shilhavy Global Research, September 29, 2021 Health Impact News 28 September 2021 Region: <u>USA</u> Theme: <u>Science and Medicine</u>

All Global Research articles can be read in 51 languages by activating the "Translate Website" drop down menu on the top banner of our home page (Desktop version).

Visit and follow us on Instagram at <u>@crg_globalresearch.</u>

Back in July of this year we reported that Ohio-based Attorney **Thomas Renz** was filing a federal lawsuit in Alabama based on a "sworn declaration, under threat of perjury," from an alleged whistleblower who claims to have inside knowledge of a cover-up of reported deaths filed with the Vaccine Adverse Event Reporting System (VAERS).

See: Attorney Files Lawsuit Against CDC Based on "Sworn Declaration" from Whistleblower Claiming 45,000 Deaths are Reported to VAERS – All Within 3 Days of COVID-19 Shots

Attorney Renz spoke at an event in Colorado this past weekend, and stated that more whistleblowers have now come forward, and that **the death rate with those taking the COVID-19 vaccines is much higher than they originally thought.**

Presenting data that he claims comes directly from the CMS (Centers for Medicare & Medicaid Services) database, there have been 48,465 deaths among CMS beneficiaries within 14 days of a 1st or 2nd dose of a COVID-19 vaccine.

There are about 59.4 million Americans covered by Medicare, representing 18.1% of the population, so these are staggering numbers!

In his presentation, Renz states that they chose deaths within 14 days of vaccination, because the federal health agencies are no longer counting deaths within 14 days of a COVID-19 as a death among the "vaccinated," but among "unvaccinated."

Remdesivir Deaths: The Real Numbers

Remdesivir (Veklury) deaths recorded in CMS database (2021):

- 7,960 beneficiaries prescribed Remdesivir for COVID-19
- 2,058 beneficiaries died

25.9% remdesivir patients died

46% of those died within 14 days of remdesivir treatment

How much does remdesivir cost?

Hospitals will pay \$390 per vial of remdesivir, which equates to \$2,340 (government) to \$3,120 (private insurance) for a five-day course of the drug, using 6 vials

(source: https://www.kff.org/coronavirus-covid-19/issue-brief/how-could-the-price-of-remdesivir-impact-medicare-spending-for-covid-19-patients/)

Renz also presented very damning data on the drug Remdesivir, the new COVID-19 drug that was rushed to market while existing, safe and effective older drugs like Ivermectin are prohibited in hospital settings.

According to CMS data, almost 26% of people put on Remdesivir die. But it is a huge money maker for the government and Big Pharma.

Sa		Cheaper desivir	Than
		9	
Ivermectin Safety Profile as shown in the CMS data			
Universe	# Beneficiaries Prescribed Ivermectin in 2021	# Beneficiaries who died	% Beneficiaries who died
All patients	142,778	5,093	3.5%
COVID patients	44,709	3,238	7.2%
patients vermectin ave	rage amount p	ber patient: \$24 to \$3,120 for (4

By contrast, only 3.5% of people put on Ivermectin died, according to CMS data. But there are no longer any patents on Ivermectin, so it is not a money maker for the government and Big Pharma.

As attorney Renz states: "You're being defrauded by your government!"

He also goes on to show what are allegedly documents from Pfizer that seem to suggest they knew that "shedding" occurred with their COVID-19 mRNA shots.

Here is the presentation. I have excerpted the key data he presented. This is from our <u>Bitchute channel</u>, and it will also be on our <u>Rumble channel</u>.

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, @crg_globalresearch. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

The original source of this article is <u>Health Impact News</u> Copyright © <u>Brian Shilhavy</u>, <u>Health Impact News</u>, 2021

Comment on Global Research Articles on our Facebook page

Become a Member of Global Research

Articles by: Brian Shilhavy

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

<u>www.globalresearch.ca</u> contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca